Evidence map›Paper›PMID 34690467›Full record

ReviewJournal of King Saud University. Science2021

SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines.

Palaniyandi Velusamy, Kannan Kiruba, Chia-Hung Su, Viswanathan Arun, Periasamy Anbu, Subash C B Gopinath, Baskaralingam Vaseeharan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of King Saud University. Science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 4 countries.

Palaniyandi VelusamyResearch and Development Wing, Central Research Laboratory, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research (BIHER), Chennai- 600 044, TN, India.
Kannan KirubaDepartment of Biotechnology, University of Madras, Guindy Campus, Chennai 600 025, TN, India.
Chia-Hung SuDepartment of Chemical Engineering, Ming Chi University of Technology, Taishan, Taipei 24301, Taiwan.
Viswanathan ArunDepartment of Biotechnology SRFBMST, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai 600 116, TN, India.
Periasamy AnbuDepartment of Biological Engineering, College of Engineering, Inha University, Incheon 402-751, Republic of Korea.
Subash C B GopinathFaculty of Chemical Engineering Technology and Institute of Nano Electronic Engineering, Universiti Malaysia Perlis, Arau 02600, Perlis, Malaysia.
Baskaralingam VaseeharanNanobiosciences and Nanopharmacology Division, Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Science Campus 6th Floor, Karaikudi 630 004, Tamil Nadu, India.
Alagappa University · INBharath University · INInha University · KRMing Chi University of Technology · TWSri Ramachandra Institute of Higher Education and Research · INUniversiti Malaysia Perlis · MYUniversity of Madras · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell

Indexed as

CoronavirusSARS-CoV2Spike ProteinVaccineVirus Entry

Identifiers

PMID34690467
PMCPMC8523302
OpenAlexW3206007441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.